EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access

Estimated Lifetime Gained With Cancer Screening Tests

Michael Bretthauer, Paulina Wieszczy, Magnus Løberg, Michal F Kaminski, Tarjei Fiskergård Werner, Lise M Helsingen, Yuichi Mori, Øyvind Holme, Hans-Olov Adami, Mette Kalager

JAMA Internal Medicine · 01.11.2023 · 183 (11) · 1196

DOI: 10.1001/jamainternmed.2023.3798 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift JAMA Internal Medicine, erschienen am 01.11.2023. Verfasst von Michael Bretthauer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Effectiveness Research Group, Institute of Health and Society, University of Oslo, Department for Transplantation Medicine, Oslo University …. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Lung Neoplasms, Colorectal Neoplasms. Die Arbeit wurde bisher 150-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Cancer screening tests are promoted to save life by increasing longevity, but it is unknown whether people will live longer with commonly used cancer screening tests.

Objective

To estimate lifetime gained with cancer screening. Data Sources A systematic review and meta-analysis was conducted of randomized clinical trials with more than 9 years of follow-up reporting all-cause mortality and estimated lifetime gained for 6 commonly used cancer screening tests, comparing screening with no screening. The analysis included the general population. MEDLINE and the Cochrane library databases were searched, and the last search was performed October 12, 2022. Study Selection Mammography screening for breast cancer; colonoscopy, sigmoidoscopy, or fecal occult blood testing (FOBT) for colorectal cancer; computed tomography screening for lung cancer in smokers and former smokers; or prostate-specific antigen testing for prostate cancer. Data Extraction and Synthesis Searches and selection criteria followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guideline. Data were independently extracted by a single observer, and pooled analysis of clinical trials was used for analyses. Main Outcomes and Measures Life-years gained by screening was calculated as the difference in observed lifetime in the screening vs the no screening groups and computed absolute lifetime gained in days with 95% CIs for each screening test from meta-analyses or single randomized clinical trials.

Results

In total, 2 111 958 individuals enrolled in randomized clinical trials comparing screening with no screening using 6 different tests were eligible. Median follow-up was 10 years for computed tomography, prostate-specific antigen testing, and colonoscopy; 13 years for mammography; and 15 years for sigmoidoscopy and FOBT. The only screening test with a significant lifetime gain was sigmoidoscopy (110 days; 95% CI, 0-274 days). There was no significant difference following mammography (0 days: 95% CI, −190 to 237 days), prostate cancer screening (37 days; 95% CI, −37 to 73 days), colonoscopy (37 days; 95% CI, −146 to 146 days), FOBT screening every year or every other year (0 days; 95% CI, −70.7 to 70.7 days), and lung cancer screening (107 days; 95% CI, −286 days to 430 days). Conclusions and Relevance The findings of this meta-analysis suggest that current evidence does not substantiate the claim that common cancer screening tests save lives by extending lifetime, except possibly for colorectal cancer screening with sigmoidoscopy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsLung NeoplasmsColorectal NeoplasmsMaleHumansEarly Detection of CancerProstate-Specific AntigenMass ScreeningRandomized Controlled Trials as TopicColonoscopyOccult Blood

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Clinical Effectiveness Research Group, Institute of Health and Society, University of Oslo, Department for Transplantation Medicine, Oslo University Hospital, Oslo, Norway.
  • Department of Gastroenterology, Hepatology and Clinical Oncology, Centre of Postgraduate Medical Education, Warsaw, Poland.
  • Department of Cancer Prevention and Oncological Gastroenterology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Medical Library, University of Oslo and Oslo University Hospital, Oslo, Norway.
  • Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan.
  • Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.

Zitieren

APA

Bretthauer, M., Wieszczy, P., Løberg, M., Kaminski, M. F., Werner, T. F., Helsingen, L. M., Mori, Y., Holme, Ø., Adami, H. O., & Kalager, M. (2023). Estimated Lifetime Gained With Cancer Screening Tests. JAMA Internal Medicine, 183(11), 1196. https://doi.org/10.1001/jamainternmed.2023.3798

Vancouver

Bretthauer M, Wieszczy P, Løberg M, Kaminski MF, Werner TF, Helsingen LM, et al. Estimated Lifetime Gained With Cancer Screening Tests. JAMA Internal Medicine. 2023;183(11):1196. doi:10.1001/jamainternmed.2023.3798

BibTeX
@article{Bretthauer2023,
  author = {Bretthauer, Michael and Wieszczy, Paulina and Løberg, Magnus and Kaminski, Michal F and Werner, Tarjei Fiskergård and Helsingen, Lise M and Mori, Yuichi and Holme, Øyvind and Adami, Hans-Olov and Kalager, Mette},
  title = {Estimated Lifetime Gained With Cancer Screening Tests},
  journal = {JAMA Internal Medicine},
  year = {2023},
  volume = {183},
  number = {11},
  pages = {1196},
  doi = {10.1001/jamainternmed.2023.3798}
}
Kostenlos starten →